Incobotulinum toxin A

Phase 2Small molecule

NNorthwestern University

Incobotulinum toxin A is one of 112 small molecule programs targeting Parkinsonism. It is currently in Phase 2.

Indications

Total Trials

Active Trials

111

Competitors

Pipeline

Status by Indication[3][1]

Indication

ParkinsonismActive, not recruiting

TinnitusActive, not recruiting

Amyotrophic Lateral SclerosisActive, not recruiting

Multiple SclerosisActive, not recruiting

WrinklesActive, not recruiting

ParkinsonismPhase 2

Active, not recruiting

TinnitusPhase 2

Active, not recruiting

Amyotrophic Lateral SclerosisPhase 2

Active, not recruiting

Multiple SclerosisPreclinical

Active, not recruiting

WrinklesPhase 1

Active, not recruiting

Competition

Competitive Landscape

560 competitors in Multiple Sclerosis

#DrugCompanyPhaseTrials

Incobotulinum toxin A

NNorthwestern University

Phase 2

1 2

Betaseron

Bayer

Preclinical

16 3

Kesimpta

Novartis

Preclinical

15 4

Tysabri

Biogen

Preclinical

14 5

Avonex

EMD Serono

Preclinical

22 6

Campath

GGenzyme, a Sanofi Company

Preclinical

12 7

Zinbryta

Roche

Preclinical

2 8

Flomax

Sanofi

Preclinical

1 9

Novantrone

Pred Forte

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Function

NCT07486830

Q4 2027

Phase 1Active, not recruiting

Wrinkles

NCT02019004

Clinical

Trials by Indication[1]

Multiple Sclerosis1 trial

Therapeutic Benefit of Incobotulinum Toxin A for Spasticity of the Triceps Surae in Patients With Multiple Sclerosis

Completed·PPôle Saint Hélier··NCT04265092·22 enrolled

Parkinsonism1 trial

Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism

Completed·—·Phase 2·NCT01653132·10 enrolled

Function1 trial

IncobotulinumtoxinA for Provoked Vestibulodynia With Overactive Pelvic Floor Muscle Dysfunction

Recruiting·CCenter for Vulvovaginal Disorders·Phase 2·NCT07486830·54 enrolled

Amyotrophic Lateral Sclerosis1 trial

Incobotulinum Toxin A for Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS)

Withdrawn·—·Phase 2·NCT01565395

Tinnitus1 trial

The Efficacy of Incobotulinum Toxin A Injections for Treatment of Tinnitus: a Randomized Controlled Trial

Completed·UUniversity of Minnesota·Phase 2·NCT05650645·41 enrolled

2 more indications

Botulinum Toxin1 trial

Clinical Effects of Incobotulinum Toxin vs Corticosteroid in Plantar Fascitis

Active, not recruiting·IInstituto Mexicano del Seguro Social·Phase 1·NCT06788158·20 enrolled

Wrinkles1 trial

Treatment of Forehead/Glabellar Rhytide Complex With Onabotulinum Toxin A Versus Incobotulinum Toxin A Injection: A Split-face, Double-blinded, Randomized Control Trial

Active, not recruiting·NNorthwestern University·Phase 1·NCT02019004·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Incobotulinum toxin A. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Incobotulinum toxin A compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Incobotulinum toxin A. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Northwestern University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNorthwestern University

Incobotulinum toxin A

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2027

Trials by Indication[1]

Multiple Sclerosis1 trial

Parkinsonism1 trial

Function1 trial

Amyotrophic Lateral Sclerosis1 trial

Tinnitus1 trial

Botulinum Toxin1 trial

Wrinkles1 trial

References

Drug Info

Quick Facts

Related News